Procedure: Guidelines for Perioperative Management of Buprenorphine
(Suboxone/Subutex)

Date: March 11, 2013
Department: Anesthesia

Personnel Responsible: All physicians

(No PPE required.)

**Purpose:** To provide adequate postoperative pain relief.

**Procedure:**

Buprenorphine is currently used for opioid and heroin addiction and also used for the management of pain. There has been an increase in the number of patients presenting for surgery taking buprenorphine. Buprenorphine is a partial agonist/antagonist with a very long half-life and tight receptor binding. Pain treatment with opioids is complicated by the high affinity of buprenorphine for the mu receptor. This high affinity risks displacement of, or competition with, full opioid agonist analgesics when buprenorphine is administrated concurrently or sequentially. As such, its effects can inhibit the efficacy of opioids in the postoperative course and patients are likely to experience poor post-operative analgesia. This can lead to uncontrolled pain and the potential for serious adverse events. Two preparations are available:

1. **Subutex:** Buprenorphine
2. **Suboxone:** Buprenorphine and naloxone

Perioperative pain management guidelines for patients on buprenorphine:

- **Minor Operations/Day Cases** (Elective and Urgent/Emergent Admissions) *(Minor Operations are those that only require either local with sedation or monitored anesthesia care)*
  1. Continue buprenorphine maintenance therapy and titrate a short-acting opioid analgesic to effect.
  2. Maximize non-opioid analgesia, regional techniques and adjunctive therapy.
  3. **OB patients:** both laboring and elective/non elective C- sections recommend not stopping the buprenorphine for these pregnant patients. Postop analgesic plan C- sections: CSE so that the epidural catheter may be used postop.
• **Major Operations** (Elective Admissions)

1. Send the fax memo to the surgeon recommending that the last dose of buprenorphine be 4 days prior to surgery date. The surgeon should ensure that the prescribing physician is aware of the upcoming surgery. Buprenorphine withdrawal peaks at 3-4 days and symptoms may persist for 7 days. In computing transition opioid doses, IV buprenorphine is at least 25 times more potent than IV morphine in analgesic efficacy. However, such transitions should be conservative in the outpatient setting, and a much lower dose will suffice for this short duration of transition, i.e. oxycodone 40mg/day (10mg QID), is sufficient to prevent withdrawal syndrome.

2. Anticipate patient’s course will be similar to a chronic opioid tolerant patient.

3. Regional analgesia – consider epidural or peripheral nerve catheter.

4. IV PCA.

5. Maximize adjuncts, e.g. Ketamine.

6. Maximize non-opioid therapy, e.g. Tylenol, NSAIDS.

7. Restarting buprenorphine is done at the discretion of the prescribing physician.

• **Major Operations** (Urgent/Emergent Admissions)

1. Discontinue buprenorphine. Surgeons should ensure that the prescribing physician is aware of the upcoming surgery.

2. Anticipate patient’s course will be similar to a chronic opioid tolerant patient.

3. Regional analgesia – consider epidural or peripheral nerve catheter.

4. IV PCA.

5. Maximize adjuncts, e.g. Ketamine.

6. Maximize non-opioid therapy, e.g. Tylenol, NSAIDS.

7. It is important to remember that the dose requirement of an opioid may drop as the buprenorphine dissociates from the mu receptor, which may take 24-72 hours after the last dose.

8. Restarting buprenorphine is done at the discretion of the prescribing physician.
References

Dated: 03/11/13

(Review/Revision dates 3 years earlier may be found on file.)

Reviewed:

Revised:

<table>
<thead>
<tr>
<th>Submitted by:</th>
<th>Reviewed by:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Director:</td>
<td>Approved by:</td>
</tr>
</tbody>
</table>


Dear Doctor,

Your patient is scheduled for a painful surgical procedure at Stephens Memorial Hospital as noted above.

Pre-operative evaluation has revealed this patient is taking Buprenorphine. Patients who take their buprenorphine up until the day of surgery are likely to experience poor post-operative analgesia. They require large doses of opioid with often inadequate pain relief. This issue involves more than the expected opioid tolerance in these patients. It is a result of two features of buprenorphine:

- Avid and prolonged mu receptor binding.
- Limited analgesic activity (“analgesic ceiling”).

You will need to contact the patient’s prescribing physician and ensure that they are aware of your patient’s surgery date. Literature indicates that buprenorphine withdrawal peaks at 3-4 days and symptoms persist for 7 days. Although challenges persist, we have found that these patients fare best when they are taken off their buprenorphine and transitioned to a pure mu receptor agonist for a number of days prior to surgery to prevent withdrawal symptoms. In computing transition opioid doses, IV buprenorphine is at least 25 times more potent than IV morphine in analgesic efficacy. However, such transitions should be conservative in the outpatient setting. A lower dose, e.g. oxycodone 40mg/day, will generally suffice for the prevention of withdrawal symptoms during this brief transition period.

**Therefore, please direct the last dose of Buprenorphine to be 4 DAYS prior to the date of surgery.**

Thank you for your help with this patient. If there are any questions, please contact the anesthesiologist on call at 207-743-5933 ext. 6702 during business hours. If calling after hours, please ask for the on call anesthesiologist to be paged.